[Moexipril influence on quality of life in postmenopausal women with arterial hypertension].
To evaluate a hypotensive effect and metabolic neutrality and safety of ACE inhibitor moexipril in postmenopausal women with arterial hypertension (AH), influence on quality of life. Thirty two hypertensive postmenopausal women (age 63.1 +/- 0.8 years) received moexipril for 4 months. The history of AH was 10.4 +/- 2.3 years, on the average. After a free of drugs week moexipril was given in a dose 7.5 mg/day with titration to 15 mg in 2 weeks and addition (if the target pressure was not achieved) of hydrochlorothiaside in a dose 12.5 mg. The examination included 24-h monitoring of blood pressure, estimation of microalbuminuria (MAU), endothelial function and blood biochemistry. Initially and after 4 weeks of the treatment quality of life was assessed (scales SF-36 and EuroQol). The initial level of office BP was 164.33/94.50 mm Hg, in 3 months a target level was achieved (136/84 mm Hg). It persisted for the next month. Moexipril corrected endothelial function and vascular elasticity in all the patients. MAU fell from 28.28 to 8.10 mg/l. Quality of life improved. Lipid and carbohydrate changes were not registered. Moexipril has a hypotensive and nephroprotective effects, improves endothelial function and quality of life in hypertensive postmenopausal women.